According to the National Cancer Institute, hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2-) is the most common breast cancer subtype, accounting for about 68% of cases from 2014 to 2018. After traditional first-line endocrine monotherapy, the disease typically progresses despite the initial high rate of clinical benefit. Studies have aimed at optimizing treatment strategies to improve on clinical benefit beyond the traditional single-agent endocrine treatment. With the availability of new data and novel therapies, the clinical practice challenge becomes how best to define the optimal treatment sequence to maximize clinical benefit.
What do you know about HR+/HER2- breast cancer? Test your knowledge with this quick quiz.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Winston W. Tan. Fast Five Quiz: HR-Positive/HER2-Negative Breast Cancer - Medscape - Sep 14, 2021.